The European Commission has given Holoclar®, the first advanced therapy medicinal product (ATMP) containing stem cells, conditional marketing authorisation following a recommendation for approval by the European Medicines Agency.
Not many researchers go directly into schools to teach science lessons, but that’s what Professor Ian Chambers from the MRC Centre for Regenerative Medicine did when he teamed up with EuroStemCell science communicator Emma Kemp. They have just published an academic paper on their experience of bringing stem cell research into schools. Here’s what they learned.
Two recent studies have revealed for the first time how to to generate insulin producing cells, that resemble normal beta cells, in the lab from human pluripotent stem cells. This provides a step forward for a potential cell therapy treatment for diabetes. But how alike are these cells to the beta cells found in our bodies? How close are we to testing these cells in diabetics? And what other questions still remain? In this commentary, Henrik Semb tackles these questions providing perspective in this complex and challenging field.